showed that the reduction of Th17 cells in a mouse model of RA by blocking IL-6 may be partially dependent on the inhibition of AhR expression and that AhR antagonists are therefore a promising therapeutic agent for RA (121). This evidence concerns the gene AHR and rheumatoid arthritis.